Trinomab Biotech

China’s Center for Drug Evaluation (CDE) has accepted Trinomab Biotech Co., Ltd.’s market approval filing for its antitetanus toxin monoclonal antibody (mAb) injection, TNM002, for review. TNM002, developed using Trinomab’s proprietary HitmAb technology platform, has demonstrated strong drug specificity, favorable safety profiles, and exceptional efficacy in neutralizing tetanus toxin in…